Stroke is a leading cause of death and disability, and there has been intense clinical research into identifying objective measurements or diagnostics for stroke, including triaging stroke and stroke mimics.. Among the recognised biomarkers for stroke are the purines: adenosine, inosine and hypoxanthine, which are downstream metabolites of adenosine-triphosphate (ATP).
At the time of writing the note clinical studies have been performed on correlating the purines in venous blood with stroke and epilepsy, and studies are on going with testing capillary blood for purines.. From these initial studies the time window in which purine levels are raised and indicative of stroke is approximately 4.5 hours.
ZP is looking to expand our work with clinicians to utilize our ZP Accelerator platform as part of our validation of purine biomarkers for tissue damage related conditions.